menu
    • menu
    [{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Evoq Therapeutics \/ Amgen","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Amgen"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0.66000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.66000000000000003,"dosageForm":"","sponsorNew":"Evoq Therapeutics \/ Gilead","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Gilead"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Evoq Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Evoq Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Evoq Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"14","companyTruncated":"Evoq Therapeutics \/ National Institutes of Health"}]

    Find Clinical Drug Pipeline Developments & Deals by Evoq Therapeutics

    Menu

    Evoq Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evoq Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Evoq Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Sponsor : National Institutes of Health

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            EVOQ Therapeutics Secures $2 Million NIH Grant

                            Details : The Company intends to use the proceeds to accelerate the development of its platform and advance novel therapies for autoimmune diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 29, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Sponsor : National Institutes of Health

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Evoq Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Evoq Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Amgen Inc

                            Deal Size : $240.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            EVOQ Therapeutics and Amgen Expanding Collaboration

                            Details : Amgen and EVOQ Therapeutics are collaborating on preclinical development of novel drugs using EVOQ's NanoDisc platform. Amgen is responsible for clinical development and commercialization of the resulting products.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 18, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Amgen Inc

                            Deal Size : $240.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Evoq Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Evoq Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Gilead Sciences

                            Deal Size : $658.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies

                            Details : Under the agreement, Gilead has the option to exclusively license rights to EVOQ’s NanoDisc technology to pursue product candidates for RA and lupus indications and will be responsible for clinical development and commercialization.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 03, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Gilead Sciences

                            Deal Size : $658.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Evoq Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Evoq Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Amgen Inc

                            Deal Size : $240.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen

                            Details : Under the terms of the agreement, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 13, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Amgen Inc

                            Deal Size : $240.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth